- Home
- CCS vs GLPG Comparison
CCS vs GLPG Comparison
Compare CCS & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCS
- GLPG
- Stock Information
- Founded
- CCS 2000
- GLPG 1999
- Country
- CCS United States
- GLPG Belgium
- Employees
- CCS N/A
- GLPG N/A
- Industry
- CCS Homebuilding
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- CCS Consumer Discretionary
- GLPG Health Care
- Exchange
- CCS Nasdaq
- GLPG Nasdaq
- Market Cap
- CCS 1.7B
- GLPG 1.9B
- IPO Year
- CCS 2014
- GLPG 2005
- Fundamental
- Price
- CCS $58.88
- GLPG $31.21
- Analyst Decision
- CCS Buy
- GLPG Sell
- Analyst Count
- CCS 5
- GLPG 4
- Target Price
- CCS $80.75
- GLPG $25.33
- AVG Volume (30 Days)
- CCS 412.0K
- GLPG 222.2K
- Earning Date
- CCS 07-23-2025
- GLPG 07-23-2025
- Dividend Yield
- CCS 1.94%
- GLPG N/A
- EPS Growth
- CCS 7.67
- GLPG N/A
- EPS
- CCS 9.70
- GLPG N/A
- Revenue
- CCS $4,352,977,000.00
- GLPG $311,493,731.00
- Revenue This Year
- CCS N/A
- GLPG $0.78
- Revenue Next Year
- CCS $7.90
- GLPG N/A
- P/E Ratio
- CCS $6.18
- GLPG N/A
- Revenue Growth
- CCS 11.97
- GLPG 18.32
- 52 Week Low
- CCS $50.42
- GLPG $22.36
- 52 Week High
- CCS $108.42
- GLPG $31.39
- Technical
- Relative Strength Index (RSI)
- CCS 56.33
- GLPG 70.92
- Support Level
- CCS $57.16
- GLPG $30.06
- Resistance Level
- CCS $62.04
- GLPG $30.78
- Average True Range (ATR)
- CCS 2.31
- GLPG 0.50
- MACD
- CCS -0.02
- GLPG 0.19
- Stochastic Oscillator
- CCS 53.14
- GLPG 99.10
About CCS Century Communities Inc.
Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.